NexGel, Inc. filed a Form 8-K on November 12, 2026, disclosing agreements entered on November 10, 2026, covering note amendment and conversion arrangements with convertible noteholders and a private placement of common stock and warrants, as part of a recapitalization intended to precede a potential merger with Fountainhead LifeSciences and its affiliates.
Key Highlights
- Conversion Agreements: Holders of approximately $14.125 million of the $14.885 million aggregate outstanding principal of convertible promissory notes issued in April and May 2026 agreed to convert 100% of their notes into common stock at $5.50 per share.
- Accrued Interest Conversion: Interest accrued through September 30, 2026 is to be received in common stock at $12.00 per share; interest accruing from October 1, 2026 is suspended pending conversion closing.
- Private Placement: The company agreed to sell common stock at $5.50 per share, each with a five-year warrant to purchase one share at $10.00 per share, with $1.276 million in commitments received for the initial closing, including $732 thousand from Sequence.
- Related Party Context: Sequence LifeSciences, Inc., which is wholly owned by Brian Kieser, the company's Interim Chief Executive Officer and a director, committed $732 thousand to the initial closing, and the proposed merger would constitute a related party transaction, according to the filing.
- Merger Structure: Common stock issued to Fountainhead in the merger is to represent no less than 45% and no more than 50% of fully diluted shares, as defined in the Conversion Agreements, with a management incentive pool of approximately 6% of fully diluted shares to be disclosed.
- Outside Date: If the merger is not consummated by March 31, 2027, conversion elections terminate, notes remain outstanding on amended terms, and forbearance ends, with interest reinstated retroactively to October 1, 2026.
- Reverse Split: All share and per-share amounts in the filing give effect to the 1-for-20 reverse stock split that became effective October 12, 2026.
NexGel's Note Conversion and New Capital Financing: Terms and Conditions
According to the Form 8-K filed with the SEC, NexGel, Inc. (NASDAQ:NXGL) entered into Note Amendment and Conversion Agreements on November 10, 2026 with holders representing approximately $14.125 million of the $14.885 million aggregate outstanding principal of convertible promissory notes originally issued in April and May 2026. Each participating holder irrevocably elected to convert 100% of its notes into common stock at $5.50 per share and to receive interest accrued through September 30, 2026 in common stock at $12.00 per share. The conversion will become effective only upon completion of the merger and satisfaction of other specified conditions, including receipt of an independent valuation and fairness opinion by a special committee of independent directors, required stockholder and Nasdaq approvals, and executed agreements from all holders other than holders of up to $1.0 million of aggregate principal.
Simultaneously, the company entered into a Securities Purchase Agreement for a private placement of common stock at $5.50 per share, each accompanied by a five-year warrant to purchase one share at $10.00 per share, exercisable for cash only. The filing states that $1.276 million in commitments have been received for the initial closing, including $732 thousand from Sequence LifeSciences, Inc., which is wholly owned by Brian Kieser, the company's Interim Chief Executive Officer and a director. The company disclosed it intends to use proceeds for working capital and transaction expenses, and not to repay the notes. Alere Financial Partners, a division of Cova Capital Partners, LLC, was engaged as non-exclusive placement agent, with the company expecting to pay Alere a cash fee of $54.3 thousand and to issue warrants to purchase 9,878 shares at the initial closing.
The filing notes that the transactions are part of a recapitalization intended to precede a potential merger with Fountainhead LifeSciences and its affiliates, including Sequence and NVISION Biomedical Technologies, Inc. The company disclosed that it has not entered into a definitive agreement for the merger, and stated: "there is no assurance that it will do so or that the Merger will be completed." The exercise price of five-year warrants issued with the original notes was reduced to $13.00 per share ($0.65 before the reverse split) as part of amendments that took effect at signing.
What Was Disclosed
NexGel disclosed entry into note amendment and conversion agreements covering approximately $14.125 million of outstanding convertible note principal, alongside a private placement of common stock and warrants, in connection with a planned but not yet definitively agreed recapitalization and potential merger with Fountainhead LifeSciences and its affiliates.




Please wait processing your request...